tiprankstipranks
Trending News
More News >

Palisade Bio Appoints Emil Chuang as New Director

Story Highlights
Palisade Bio Appoints Emil Chuang as New Director

Don’t Miss TipRanks’ Half-Year Sale

Palisade Bio ( (PALI) ) has provided an announcement.

Palisade Bio Inc. announced the resignation of Margery Fischbein from its Board of Directors on July 2, 2025, with no disagreements cited regarding company operations. Her contributions were acknowledged by accelerating the vesting of her stock options. Subsequently, on July 7, 2025, Emil Chuang was appointed as a new director, filling the vacancy. Dr. Chuang will serve on several committees and receive stock options and compensation as per the company’s non-employee director program.

The most recent analyst rating on (PALI) stock is a Buy with a $22.50 price target. To see the full list of analyst forecasts on Palisade Bio stock, see the PALI Stock Forecast page.

Spark’s Take on PALI Stock

According to Spark, TipRanks’ AI Analyst, PALI is a Neutral.

Palisade Bio’s financial struggles dominate the overall assessment with consistent losses and negative cash flow posing significant risks. Despite a stable balance sheet due to low leverage, the lack of profitability and reliance on external funding are concerning. Technical analysis shows some short-term stability, but long-term trends are negative, and valuation metrics are weak due to the negative P/E ratio.

To see Spark’s full report on PALI stock, click here.

More about Palisade Bio

Average Trading Volume: 309,389

Technical Sentiment Signal: Strong Sell

Current Market Cap: $3.52M

For an in-depth examination of PALI stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1